A federal genetic-testing case has produced one of the summer’s largest health-care fraud settlements, with three parties agreeing to pay a combined $36.4 million. The money resolves allegations that Medicare and Medicaid were billed for medically unnecessary tests generated through kickbacks, a financing chain that can turn an ordinary cheek swab into a costly claim against public health programs.
Three agreements make up the $36.4 million total
The Justice Department announced July 30 that Houston-based Access DX Laboratory, former chief executive Michael Stewart and Florida businessman Harold Shatz entered settlements requiring a combined $36.4 million payment. The agreements resolve civil allegations under the False Claims Act; the settlements are not judicial findings that the parties committed the alleged conduct.
Federal lawyers said the arrangements involved payments to independent contractor sales representatives and other marketers who referred or arranged genetic testing. The government alleged that the compensation depended on the volume or value of referrals and that the resulting claims included tests that were not reasonable and necessary. Medicare and Medicaid therefore sat at the end of a sales system whose financial incentives allegedly ran backward from a reimbursable test.
Free retirement updates: Scam calls targeting retirees change every week. Our free Retirement Shield newsletter flags the ones going around and the one tell that stops each. Sign up free.
Kickbacks can distort the medical-necessity decision
The financial problem is not that every genetic test is suspect. A properly ordered test can help diagnose or guide treatment for a patient whose medical history supports it. The danger arises when compensation rewards a marketer for delivering a billable specimen rather than helping a clinician answer a defined medical question. That incentive can increase both the number and the breadth of panels submitted for payment.
Federal health programs restrict remuneration for referrals because it can influence what care is recommended and where it is provided. The HHS inspector general’s current fraud-and-abuse law guide explains that prohibited remuneration may include cash as well as items or services. For patients, a laboratory’s promise that testing is “covered” does not establish that it is medically necessary or that no later billing issue will arise.
The whistleblower share reaches $7.2 million
The case began with a lawsuit filed under the False Claims Act’s qui tam provisions, which permit a private person to sue on the government’s behalf and share in a recovery. DOJ said the relator, the president of a Massachusetts marketing company hired to market Access DX testing, will receive approximately $7.2 million from the settlements. That award is paid from the government’s recovery and reflects the role people close to a billing arrangement can play in exposing claims patterns that ordinary beneficiaries cannot see.
The Justice Department’s False Claims Act description separates this civil mechanism from a criminal conviction. The law can impose liability when false claims are knowingly presented, while a negotiated settlement may expressly resolve allegations without an admission of liability. That distinction matters in a case whose headline dollar amount is definite even though the conduct remains framed as alleged.
Medicare statements can reveal the downstream charge
A beneficiary may never see the marketer-to-laboratory payment arrangement, but a Medicare Summary Notice can reveal the resulting claim. Unfamiliar laboratory names, repeated genetic panels or tests that were never discussed with a treating clinician warrant a call to the provider and the number shown on the notice. A claim marked paid does not mean the beneficiary personally owes the listed amount, yet it still represents program money that affects Medicare’s finances.
Medicare’s official fraud-reporting page asks beneficiaries to compare the provider, service and date with their records before reporting suspected fraud. Useful documentation includes the notice, the name of anyone who offered the test, shipping labels from a mailed kit and notes about what was promised. Reports should focus on the concrete mismatch rather than a diagnosis about whether a crime occurred.
Public-program losses ultimately reach household finances
Program-integrity recoveries do not operate like refunds mailed to individual Medicare enrollees. Settlement money generally returns to government funds according to the agreements, while the beneficiary’s practical protection is preventing an inaccurate health record and avoiding later collection attempts. A questionable diagnosis can also follow a patient into future medical decisions if it is not corrected with the ordering clinician or plan.
The July 30 agreements put a precise price on the government’s civil resolution: $36.4 million across the laboratory, its former executive and a businessman. They also show why older patients should treat unsolicited testing offers as financial transactions as well as medical ones. A test should begin with a clinician’s documented need, not with a marketer’s assurance that Medicare will pick up the bill.
Billing questions should be separated from treatment decisions
A patient who discovers a questionable claim should not cancel follow-up care solely because a laboratory appears in an enforcement case. The treating clinician can explain whether a test influenced a diagnosis and whether a valid repeat or alternative is necessary. Medicare can address the payment record, while the medical office corrects the clinical record; handling both tracks prevents a billing dispute from creating a gap in care.
This article was researched and drafted with AI assistance and reviewed against the linked primary sources.
More Financial Reading
- How many CDs can you park at 1 bank? FDIC rules you must know
- Bank statements: how long to keep them and when to toss them
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
